FR941103-2-00085 FR941103-2-00043 DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. 94N&hyph;0392] Fujisawa USA, Inc; Withdrawal of Approval of a New Drug Application AGENCY: Food and Drug Administration, HHS. ACTION: Notice. SUMMARY: The Food and Drug Administration (FDA) is withdrawing approval of a new drug application (NDA) held by Fujisawa USA, Inc., Parkway North Center, Three Parkway North, Deerfield, IL 60015&hyph;2548 (Fujisawa). FDA is withdrawing approval of this application because of questions raised about the reliability of the data and information submitted to FDA in support of the application. Marketing of the drug has been discontinued, and Fujisawa has voluntarily requested withdrawal of approval of the application and has waived its opportunity for a hearing. EFFECTIVE DATE: November 3, 1994. FOR FURTHER INFORMATION CONTACT: Tamar S. Nordenberg, Center for Drug Evaluation and Research (HFD&hyph;366), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301&hyph;594&hyph;2041. SUPPLEMENTARY INFORMATION: Recently, FDA became aware of discrepancies in the data used to support approval of the following NDA held by Fujisawa: NDA 18&hyph;440, M.V.C. 9+3. Fujisawa has identified discrepancies in data submitted to obtain approval of the application listed above, which have raised questions about the reliability of the data. In a letter dated February 22, 1994, Lyphomed requested withdrawal of this NDA. Therefore, under section 505(e) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(e)), and under authority delegated to the Director, Center for Drug Evaluation and Research (21 CFR 5.82), approval of the NDA listed above, and all amendments and supplements thereto, is hereby withdrawn, effective November 3, 1994. Distribution of drug products in interstate commerce without an approved application is unlawful. Dated: October 24, 1994. Janet Woodcock, Director, Center for Drug Evaluation and Research. [FR Doc. 94&hyph;27196; Filed 11&hyph;2&hyph;94; 8:45 am] BILLING CODE 4160&hyph;01&hyph;F
